AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Rallybio Corporation Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG011PFKG07
16.64▲ 0.24 (1.46%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
16.40
Day's Range
16.40 – 16.79
52-Week Range
0.54 – 17.57
Volume
6,186
Avg Volume
12.8K
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2021-07-29
Share count as of July 30, 2026

Rallybio Corporation Common Stock (RLYB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Rallybio Corporation Common Stock (RLYB)
What is Rallybio Corporation Common Stock's Market Cap?
Rallybio Corporation Common Stock's Market Cap is $88.4M, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Enterprise Value?
Rallybio Corporation Common Stock's Enterprise Value is -$4.5M, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Trailing P/E?
Rallybio Corporation Common Stock's Trailing P/E is 1.9×, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Price / Sales?
Rallybio Corporation Common Stock's Price / Sales is 136.8×, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's EV / Revenue?
Rallybio Corporation Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's EV / EBITDA?
Rallybio Corporation Common Stock's EV / EBITDA is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Revenue (TTM)?
Rallybio Corporation Common Stock's Revenue (TTM) is $646.0K, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Net Income (TTM)?
Rallybio Corporation Common Stock's Net Income (TTM) is $45.6M, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's EBITDA?
Rallybio Corporation Common Stock's EBITDA is -$27.7M, based on as-reported figures from SEC (XBRL) filings.
What is Rallybio Corporation Common Stock's Diluted EPS (TTM)?
Rallybio Corporation Common Stock's Diluted EPS (TTM) is 8.58, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RLYBAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-100.0%+0.0%+484.2%-29.1%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue—4219.3%2988.3%3366.5%
Loss from operations
% of revenue—-4119.3%-2888.3%-3266.5%
Other income:
Termination fee———
Interest income
Other income
Total other income, net
Income (loss) before equity in losses of joint venture
Income tax expense———
Loss on investment in joint venture
Net income (loss)
% of revenue—-3904.7%-2636.0%7554.7%
Net income (loss) per common share, basic (in dollars per share)—
Net income per common share, diluted (in dollars per share)—